Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Vascular Disorders Clear all

Conditions: Diabetic Retinopathy
Interventions: triamcinolone acetonide (Kenalog); Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetic Retinopathy
Interventions: blood draw; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 98 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Age-related Macular Degeneration, Diabetic Retinopathy, Hypertensive Retinopathy, Retinal Vein Occlusion, Retinal Artery Occlusion
Interventions: Phase variance optical coherence tomography (PV-OCT); Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 13 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Macular Degeneration
Interventions: pazopanib eye drops, Ketoconozole tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Retinal Vein Occlusion, Posterior Vitreous Detachment
Interventions: Ranibizumab; Drug
Lead sponsor: Barnes Retina Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Prompt Sham, Prompt aflibercept, Deferred laser, Deferred aflibercept; Procedure · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 81
States / cities: Phoenix, Arizona • Tucson, Arizona • Huntington Beach, California + 68 more

Conditions: Age-Related Macular Degeneration, Diabetic Retinopathy, Central Serous Chorioretinopathy, Glaucoma, Glaucoma, Suspect, Eye Diseases
Interventions: OCT Imaging Using Device N, OCT Imaging Using Device C; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Macular Edema
Interventions: NOVA63035 "Corticosteroid"; Drug
Lead sponsor: Santen SAS; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Retinal Hemangioblastoma, Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 7 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Branch Retinal Vein Occlusion
Interventions: pegaptanib sodium (Macugen); Drug
Lead sponsor: Palmetto Retina Center, LLC; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina

Conditions: Visual Impairment, Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions: In-House Developed VR Platform - AMD, DR, Glaucoma, In-House Developed VR Platform - Glaucoma; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions: Free Eye Screenings, Enhanced Intervention, Usual Care; Other
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years and older
Enrollment: 906 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Retinopathy of Prematurity
Interventions: Bevacizumab; Drug
Lead sponsor: Vision Research Foundation; Other
Eligibility: 30 Weeks to 36 Weeks
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Palo Alto, California • Miami, Florida + 14 more

Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Central Retinal Vein Occlusion
Interventions: Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 30
States / cities: Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more

Conditions: Diabetic Retinopathy
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 10 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: Fluocinolone Acetonide; Drug
Lead sponsor: Alimera Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: Lexington, Kentucky • Boston, Massachusetts • Cleveland, Ohio

Conditions: Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 5 Years to 85 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetic Retinopathy, Macular Edema
Interventions: aflibercept; Drug
Lead sponsor: Rishi Singh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Interventions: Crizanlizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 25 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Penn State University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Diabetic Retinopathy
Interventions: Color fundus photography, Mydriatic Agent; Procedure · Drug
Lead sponsor: Eyenuk, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Retinopathy
Interventions: AKST4290, Placebo; Drug
Lead sponsor: Alkahest, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Phoenix, Arizona • Glendale, California • Huntington Beach, California + 13 more

Conditions: Age-related Macular Degeneration (AMD)
Interventions: Aflibercept, Ranibizumab, Bevacizumab; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 369,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations

Anti-VEGF Treatment for Prevention of PDR/DME

Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations

Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)

Familial Investigations of Childhood Cancer Predisposition

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Blood Factors and Diabetic Retinopathy

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab

Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

Measurement of the Eye's Blood Vessels Using the Dynamic Vessel Analyzer (DVA)

Assessment of EyeArt Performance With Retinal Imaging Devices

A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)